QIAN Qingqing, JI Minchun, SUN Guangchun. Study on plasma concentration and pharmacoknetics of lamotrigine in cerebral ischemia model rats by LC-MS/MS[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 443-445,460. doi: 10.3969/j.issn.1006-0111.2018.05.013
Citation:
|
QIAN Qingqing, JI Minchun, SUN Guangchun. Study on plasma concentration and pharmacoknetics of lamotrigine in cerebral ischemia model rats by LC-MS/MS[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 443-445,460. doi: 10.3969/j.issn.1006-0111.2018.05.013
|
Study on plasma concentration and pharmacoknetics of lamotrigine in cerebral ischemia model rats by LC-MS/MS
-
Department of Pharmacy, Fifth People's Hospital of Shanghai Affiliated to Fudan University, Shanghai 200240, China
- Received Date: 2017-08-30
- Rev Recd Date:
2018-09-03
-
Abstract
Objective To establish a sensitive method for determination of concentration of lamotrigine (LTG) in rat plasma and to study the pharmacokinetics by LC-MS/MS. Methods 12 rats were divided evenly into model group and shame-operated group. LTG was given as single dose of 10 mg/kg via intragastrical administration. Blood samples were collected from orbital saphenous venous plexus at 5 min,0.25,0.5,1,2,4,6,8,12,24 and 36 h after dosing. The LTG concentrations in rat plasma were assayed by LC-MS/MS. The pharmacokinetic parameters were calculated by DAS software. Results In shame-operated group,cmax (1 382.87±61.17) μg/L,t1/2 (40.43±6.77) h; AUC0-∞(123.45±70.70) mg·h/L. In model group, cmax(1 713.50±65.11) μg/L, t1/2(73.72±17.46) h, AUC0-∞(188.15±76.37) mg·h/L. Conclusion The method is proved to be suitable for the determination of LTG in rat plasma. LTG concentration reached peak value at 2 h in both groups. However, model group had a longer t1/2 and higher concentration than that in shame-operated group, which is a valuable information for further pharmacodynamics study.
-
References
[1]
|
CALABRESI P, CUPINI LM, CENTONZE D,et al.Antiepileptic drugs as a possible neuroprotective strategy in brain ischemia[J]. Ann Neurol, 2003,53(6):693-702. |
[2]
|
YI YH, GUO WC, SUN WW, et al.Neuroprotection of lamotrigine on hypoxic-ischemic brain damage in neonatal rats:relations to administration time and doses[J]. Biologics, 2008, 2(2):339-344. |
[3]
|
SHUAIB A, MAHMOOD RH, WISHART T, et al.Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study[J]. Brain Res,1995, 702(1-2):199-206. |
[4]
|
WIARD RP, DICKERSON MC, BEEK O, et al.Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia[J]. Stroke,1995,26(3):466-472. |
[5]
|
CALABRESI P, SINISCALCHI A, PISANI A, et al.A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices[J]. Neurology, 1996,47(2):557-562. |
[6]
|
AHMAD S, FOWLER LJ, WHITTON PS, et al.Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats[J]. Naunyn Schmiedebergs Arch Pharmacol, 2005,371(1):1-8. |
[7]
|
WALKER MC, TONG X, PERRY H, et al.comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine[J]. Brit J Pharmacol, 2000, 130(2):242-248. |
[8]
|
LEE W, KIM JH, KIM HS, et al.Determination of lamotrigine in human serum by high-performance liquid chromatography-tandem mass spectrometry[J]. Neurol Sci,2010,31(6):717-720. |
[9]
|
叶广仁,宋志彬,郑国俊,等. 中国成年人拉莫三嗪药代动力学及丙戊酸对其影响[J].神经疾病与精神卫生,2007,7(3):191-193. |
-
-
Proportional views
-